Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 148 participants.
Also called NCT02162550
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 148 participants
- Sponsor
- Phoenix VA Health Care System
- Registry
-
NCT02162550
-
- Other papers using this trial's data
- The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT02162550. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2019-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Bydureon
- Intervention (Drug)
- placebo
- Lead sponsor
- Phoenix VA Health Care System
Record details
- Record id
cardio:ct-nct02162550- Content hash
76c86a40aa7f65e8787f099fda285b10a7dc364b4b817acf4d63c2337229c59c